(Bold for FDA approved)
• Blocks dopamine 2 receptors, reducing positive symptoms of psychosis
• Psychotic symptoms can improve within 1 week, but it may take several weeks for full effect on behavior
• Excitement, insomnia, restlessness
• Tardive dyskinesia (risk increases with duration of treatment and with dose)
• Risk of potentially irreversible involuntary dyskinetic movements may increase with cumulative dose and treatment duration
• Galactorrhea, amenorrhea
• Dry mouth, nausea, blurred vision, sweating, appetite change
• Sexual dysfunction (impotence)
• Hypotension, arrhythmia, tachycardia
• Weight gain
• Rare rash
• Rare neuroleptic malignant syndrome may cause hyperpyrexia, muscle rigidity, delirium, and autonomic instability with elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure
• Jaundice, leukopenia
• Rare seizures
• As a class, antipsychotics are associated with an increased risk of death and cerebrovascular events in elderly patients with dementia; not approved for treatment of dementia-related psychosis
common
unusual
• Wait
• Wait
• Wait
• For drug-induced parkinsonism, add an anticholinergic agent
• Beta blockers, benzodiazepines, or serotonin 2A antagonists (e.g., mirtazapine, cyproheptadine) may reduce akathisia
• Reduce the dose
• For sedation, take at night
• Switch to an atypical antipsychotic
• Weight loss, exercise programs, and medical management for high BMIs, diabetes, dyslipidemia
• Metformin may help prevent or reverse antipsychotic-induced weight gain
• 50–100 mg once a month
• Injection 50 mg/mL
• Should periodically reevaluate long-term usefulness in individual patients, but treatment may need to continue for many years
• No
• Use with caution
• Use with caution
• Use with caution
• Elderly patients do not metabolize the drug as quickly
• Dose should be reduced
• Recommended starting dose 5–10 mg
• Although conventional antipsychotics are commonly used for behavioral disturbances in dementia, no agent has been approved for treatment of elderly patients with behavioral symptoms of dementia such as agitation
• Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo, and also have an increased risk of cerebrovascular events
• Not recommended for use in children
• There is a risk of abnormal muscle movements and withdrawal symptoms in newborns whose mothers took an antipsychotic during the third trimester; symptoms may include agitation, abnormally increased or decreased muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty feeding
• Reports of drug-induced parkinsonism, jaundice, hyperreflexia, hyporeflexia in infants whose mothers took a phenothiazine during pregnancy
• Not recommended unless absolutely necessary
• Psychotic symptoms may worsen during pregnancy and some form of treatment may be necessary
• Atypical antipsychotics may be preferable to conventional antipsychotics or anticonvulsant mood stabilizers if treatment is required during pregnancy
• Unknown if pipothiazine is secreted in human breast milk, but all psychotropics are assumed to be secreted in breast milk
• Recommended either to discontinue drug or bottle feed
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera